Next-Generation Immunity Support.

We are looking for innovative non-pharmaceutical solutions for immune support, including food supplements, medical devices, clinically validated novel ingredients and bioactives, and microbiome-based approaches such as probiotics, prebiotics, postbiotics, and synbiotics.​

We are particularly interested in solutions that help consumers support their natural defenses and resilience, especially during periods of increased seasonal exposure, fatigue, or vulnerability. Solutions with additional potential applications in allergy relief, including the management of allergy-related symptoms, are also of interest.​

Solutions should be clinically validated, differentiated from current benchmark options, and supported by relevant regulatory authorization and claims appropriate to the product category and target market. They should be launch-ready or at an advanced stage of development, with a clear path to commercialization.​

Consumers are increasingly seeking credible, effective, and differentiated solutions to support immunity, yet many existing products remain highly commoditized with limited perceived efficacy.​

This creates an opportunity for next-generation, clinically validated solutions that deliver clear, tangible benefits, support premium positioning, and may also extend into adjacent needs such as allergy symptom management.​

Must-have Requirements.

• Demonstrated immune-support benefit, supported by robust human clinical data.​

• Relevant and supportable claims related to immune support or natural defenses, appropriate to the product category and target market.​

• Appropriate regulatory authorization or a credible regulatory pathway for food supplement and/or medical device positioning, as applicable.​

• Strong scientific rationale supporting the intended benefit.​

• Clear superiority or meaningful differentiation versus relevant benchmark solutions.​

• Launch-ready or advanced-stage solution, with demonstrated manufacturing feasibility and scalability.​

Preferred Requirements. ​

• Off-the-shelf finished product available or near-ready for commercialization​

• Proprietary or protected ingredient/technology

• Well-characterized mechanism of action​

• Convenient, consumer-friendly formats with solutions suitable for adults and children​

• Potential relevance to allergy symptom management​

Approaches​ not of interest.

•  Generic or me-too products with limited differentiation versus existing immunity solutions.​

• Solutions focused only on general wellness without a specific and substantiated immune-support benefit.​

• Early-stage formulations or concepts requiring significant further development or validation.​

• Solutions supported only by preclinical or in vitro evidence, without robust human clinical data.​

• Solutions with unclear regulatory feasibility or no credible pathway to relevant immune-support claims.​

• Products with insufficient manufacturing readiness, scalability, or commercial feasibility.​

Target Group​.

Adults and children, no specific health conditions​

Geographies​.

Global